文献速递技术与安全MR

更换钆对比剂以预防急性药物不良反应复发:基于倾向性评分匹配的6年队列研究

Changing Gadolinium-Based Contrast Agents to Prevent Recurrent Acute Adverse Drug Reactions: 6-Year Cohort Study Using Propensity Score Matching.
PubMed 文献 · Korean J Radiol · 2024-01-01

该回顾性、观察性、单中心研究纳入2016年1月至2021年12月间238743次钆对比剂增强MRI检查,聚焦发生急性钆对比剂相关药物不良反应后随访复查的患者,比较更换与不更换钆对比剂对不良反应复发的影响。结果显示更换钆对比剂组复发率显著低于不更换组(倾向性评分匹配后14.3% vs 36.9%,OR 0.32),多因素回归调整OR为0.35。

要点

  • 更换钆对比剂可能降低急性药物不良反应复发风险(调整OR 0.35,95%CI 0.13-0.90)。
  • 倾向性评分匹配后更换组复发率14.3%(6/42),不更换组36.9%(31/84)。
  • 碘对比剂过敏史与预防用药与钆对比剂急性不良反应复发无显著关联。

核心结论

  • 更换钆对比剂可能降低钆对比剂相关急性药物不良反应的复发风险。

研究设计与样本

  • 回顾性、观察性、单中心队列研究,纳入2016年1月至2021年12月间238743次连续钆对比剂增强MRI检查,随访至2023年7月。

诊断标准与关键数值

  • 急性药物不良反应总发生率为0.44%(95%CI 0.41%-0.46%)。
  • 发生急性不良反应后随访复查的患者中,31.9%(119/373)再次发生急性不良反应。
  • 多因素Logistic回归显示更换钆对比剂组复发风险显著低于不更换组(调整OR 0.35,95%CI 0.13-0.90,P=0.03)。
  • 倾向性评分匹配分析显示更换组复发率14.3%(6/42) vs 不更换组36.9%(31/84),OR 0.32(95%CI 0.11-0.94,P=0.04)。
  • 复发性过敏样超敏反应单独分析结果相似(调整OR 0.20,95%CI 0.06-0.65,P<0.01)。

临床应用与阅片要点

  • 对于既往发生钆对比剂急性不良反应的患者,更换钆对比剂可能降低再次发生急性不良反应的风险。
  • 碘对比剂过敏史(OR 1.14,95%CI 0.68-1.90,P=0.62)和预防用药(调整OR 2.09,95%CI 0.93-4.68,P=0.07)与钆对比剂急性不良反应复发无显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine the preventive effect of changing gadolinium-based contrast agents (GBCAs) to reduce the recurrence of GBCA-associated acute adverse drug reactions (ADRs).

MATERIALS AND METHODS: This retrospective, observational, single-center study-conducted between January 2016 and December 2021-included 238743 consecutive GBCA-enhanced MRI examinations. We focused on a subgroup of patients who experienced acute GBCA-associated ADRs during any of these examinations and subsequently underwent follow-up GBCA-enhanced MRI examinations up until July 2023. The follow-up examinations involved either the same (non-change group) or different (change group) GBCAs compared to the ones that initially caused the acute ADR. Baseline participant characteristics, generic profile of the GBCAs, administration of premedication, history of prior ADR to iodinated contrast media, and symptoms of GBCA-associated acute ADRs were retrospectively analyzed. Multivariable logistic regression with generalized estimating equations and propensity score matching were used.

RESULTS: A total of 1042 instances of acute ADRs (0.44%; 95% confidence interval [CI]: 0.41%-0.46%) were reported. Three-hundred and seventy-three patients underwent GBCA-enhanced MRI examinations after experiencing GBCA-associated acute ADRs within the study period; 31.9% (119/373) reexperienced acute ADRs at any of the follow-up examinations. The ADR recurrence was significantly lower in the GBCA change group than in the non-change group according to multivariable logistic regression (adjusted odds ratio [OR]: 0.35; 95% CI: 0.13-0.90; P = 0.03) and analysis with propensity score matching (14.3% [6/42] vs. 36.9% [31/84], respectively; OR: 0.32, 95% CI: 0.11-0.94; P = 0.04). A history of an ADR to iodinated contrast media (OR: 1.14, 95% CI: 0.68-1.90; P = 0.62) and premedication (adjusted OR: 2.09, 95% CI: 0.93-4.68; P = 0.07) were not significantly associated with GBCA-associated acute ADR recurrence. A separate analysis for recurrent allergic-like hypersensitivity reactions demonstrated similar results (adjusted OR: 0.20, 95% CI: 0.06-0.65; P < 0.01).

CONCLUSION: Changing GBCAs may reduce the risk of GBCA-associated acute ADR recurrence.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Han MW, Suh CH, Kim PH, et al. Changing Gadolinium-Based Contrast Agents to Prevent Recurrent Acute Adverse Drug Reactions: 6-Year Cohort Study Using Propensity Score Matching. Korean J Radiol. 2024. PMID: 39197827. doi:10.3348/kjr.2024.0248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。